<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-73069</identifier>
<setSpec>0014-2565</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">No disponible</dc:title>
<dc:description xml:lang="en">C1 inhibitor disorders are a group of rare conditions in which the C1 inhibitor is defi cientor defective. We present the clinical characteristics of 8 patients and a review of theliterature. These are characterized by recurrent episodes of angioedema, which mostoften affect the skin or mucosal tissues of the upper respiratory and gastrointestinaltract. Laryngeal involvement may cause fatal asphyxiation. These disorders may bedivided into two broad categories: hereditary angioedema (HAE) and adquired C1 inhibitordisorders. Indications for screening for HAE include: recurrent angioedema, episodic C1 inhibitor disorders are a group of rare conditions in which the C1 inhibitor is defi cientor defective. We present the clinical characteristics of 8 patients and a review of theliterature. These are characterized by recurrent episodes of angioedema, which mostoften affect the skin or mucosal tissues of the upper respiratory and gastrointestinaltract. Laryngeal involvement may cause fatal asphyxiation. These disorders may bedivided into two broad categories: hereditary angioedema (HAE) and adquired C1 inhibitordisorders. Indications for screening for HAE include: recurrent angioedema, episodic (AU)</dc:description>
<dc:creator>Arias Miranda, I</dc:creator>
<dc:creator>Rodríguez Ávila, E. E</dc:creator>
<dc:creator>Fonseca Aizpuru, E. M</dc:creator>
<dc:creator>Nuño Mateo, F. J</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El angioedema (AE) es una enfermedad infrecuente. Presentamos las características clínicasy evolución de 8 pacientes y revisamos la literatura. Se caracteriza por la ausenciao mal funcionamiento del C1 inhibidor, que se traduce en episodios de angioedema(hinchazón subcutánea o mucosa) de la piel y mucosas del tracto respiratorio superiory gastrointestinal. La afectación laríngea puede ser mortal. Puede ser hereditario o adquirido.Se debe sospechar angioedema hereditario en casos de: angioedema recurrente,dolor abdominal, edema laríngeo, historia familiar y niveles bajos de C4. En el défi citadquirido de C1 no hay antecedentes familiares. El tratamiento se divide en profi laxis acorto y a largo plazo con andrógenos, antifi brinolíticos y C1 inhibidor. Este último es deelección en ataques agudos (AU)</dc:description>
<dc:source>Rev Clin Esp;209(7): 332-336, jul.-ago.2009. tab</dc:source>
<dc:identifier>ibc-73069</dc:identifier>
<dc:title xml:lang="es">Angioedema hereditario y adquirido: características clínicas de ocho pacientes y revisión de la literatura</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d29622</dc:subject>
<dc:subject>^d29315</dc:subject>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d2694</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d32857^s22074</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d52616^s22016</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d50836</dc:subject>
<dc:subject>^d24501^s22016</dc:subject>
<dc:subject>^d24501^s22027</dc:subject>
<dc:subject>^d50836^s22033</dc:subject>
<dc:subject>^d52616^s22080</dc:subject>
<dc:type>article</dc:type>
<dc:date>200908</dc:date>
</metadata>
</record>
</ibecs-document>
